TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
Study: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
Study: NCT04638491
Drug: Lurbinectedin for injection
Normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection
Study: NCT00002876
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002876
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02381288
Drug: TAK-448
Normalized name: TAK-448
DrugBank: TAK-448 (DB11975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-448 solution for subcutaneous injection
Study: NCT02381288
Drug: TAK-448 Placebo
Normalized name: TAK-448
DrugBank: TAK-448 (DB11975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-448 placebo-matching solution for subcutaneous injection
Study: NCT03940404
Drug: Anlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
Study: NCT01738360
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~* Pre-inclusion between D-35 and D-15~* Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~* A telephone contact between D32 and D34~* A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180
Study: NCT01397084
Drug: esomeprazole 20 mg
Normalized name: esomeprazole 20 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole 20 mg once daily for 8 weeks
Study: NCT00719134
Drug: Maxalt
Normalized name: Maxalt
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anti-migraine drug
Study: NCT00369187
Drug: large protein molecule
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00764556
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
Study: NCT02534636
Drug: BMS-986165
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02534636
Drug: Interferon alpha-2a recombinant
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02534636
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00141947
Drug: bexarotene (Targretin)
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01592981
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
Study: NCT01592981
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
Study: NCT03686787
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A split face study of oral tranexamic acid in combination with laser treatment
Study: NCT02743260
Drug: pitavastatin
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02743260
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02743260
Drug: digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02743260
Drug: Adefovir
Normalized name: Adefovir
DrugBank: Adefovir (DB13868)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02743260
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03126760
Drug: Acthar Gel
Normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acthar Gel 1 mL (80U) for subcutaneous injection
Study: NCT03517956
Drug: Rogaratinib (BAY1163877)
Normalized name: Rogaratinib
DrugBank: Rogaratinib (DB15078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part.
Study: NCT03517956
Drug: Copanlisib (BAY80-6946)
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part.
Study: NCT00592384
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
Study: NCT00333814
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 350 µg; injection drug delivery system at Day 0
Study: NCT00333814
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 700 µg injection drug delivery system at Day 0
Study: NCT00333814
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection at Day 0
Study: NCT00109798
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient will take drug on day 1-5 of 28 day schedule
Study: NCT00109798
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will have IV on days 2-6 on a 28-day schedule
Study: NCT03555591
Drug: Trelagliptin
Normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Trelagliptin tablets
Study: NCT00684593
Drug: Navarixin 10 mg
Normalized name: Navarixin
DrugBank: Navarixin (DB11711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navarixin capsules orally, once daily for 28 days.
Study: NCT00670683
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT02433483
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by either intrathecal (IT) or intravenous (IV) route.
Study: NCT03780907
Drug: E2007
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg of E2007 was administered by mouth once daily.
Study: NCT03780907
Drug: E2007
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg of E2007 was administered by mouth once daily.
Study: NCT01250405
Drug: Cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
Study: NCT03571815
Drug: 5% sodium fluoride varnish
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: application of sodium fluoride varnish on teeth
Study: NCT00068471
Drug: anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00549965
Drug: Risedronate Sodium
Normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02352402
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02732119
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle
Study: NCT02732119
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
Study: NCT02732119
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: supplied in 25 mg tablets taken orally, daily for 28 day cycle
Study: NCT02269241
Drug: LF111 (drospirenone)
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
Study: NCT01246401
Drug: Extended-Release Naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
Study: NCT00767481
Drug: Travoprost/Brinzolamide
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eye drop suspension, once daily
Study: NCT02153099
Drug: TAK-058 (ENV8058)
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-058 (ENV8058) oral solution
Study: NCT00767481
Drug: Cosopt
Normalized name: Cosopt
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eye drop solution, one drop BID
Study: NCT00828321
Drug: Ramipril 10 mg capsule
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 10 mg
Study: NCT02878018
Drug: angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
Study: NCT02658487
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02658487
Drug: Vosaroxin
Normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01675115
Drug: BNG-1
Normalized name: Brentuximab vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BNG-1 3 grams TID for 4 weeks
Study: NCT01675115
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100 mg QD for 4 weeks
Study: NCT04005222
Drug: SELENIUM
Normalized name: Selenium
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
Study: NCT01354886
Drug: Gonal-f
Normalized name: Gonal-F
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 IU single dose
Study: NCT01354886
Drug: Bravelle
Normalized name: Bravelle
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 IU single dose
Study: NCT03879564
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
Study: NCT00673465
Drug: SCH 497079
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
Study: NCT00673465
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)
Study: NCT00036179
Drug: FK463
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00808977
Drug: Dersalazine sodium
Normalized name: mesalazine
DrugBank: Dersalazine (DB06251)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dersalazine sodium 2400 mg daily
Study: NCT00808977
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine 2400 mg daily
Study: NCT01856413
Drug: Zutectra
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
Study: NCT03542058
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.
Study: NCT03018704
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: anticonvulsant medication. The medication was dosed twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
Study: NCT00320411
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib 1500mg QD
Study: NCT01110434
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (200 mg daily)
Study: NCT03957720
Drug: DMPS
Normalized name: DMP-777
DrugBank: 2,3-Dimercapto-1-propanesulfonic acid (DB15967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
Study: NCT03957720
Drug: Penicillamine
Normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;
Study: NCT03957720
Drug: DMSA
Normalized name: DMSA
DrugBank: Succimer (DB00566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
Study: NCT03957720
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;
Study: NCT02332850
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02332850
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT01774058
Drug: Ilomedin
Normalized name: ferrous fumarate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
Study: NCT02847624
Drug: tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01165060
Drug: Bezafibrate
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
Study: NCT00495183
Drug: Biperiden
Normalized name: Biperiden
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biperiden 2-4 mg/d, divided in 2 doses per day.
Study: NCT02397928
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
Study: NCT02397928
Drug: Cisplatin or Carboplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
Study: NCT04135898
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3mg/kg, infusion in 90 minutes
Study: NCT00582166
Drug: Ibritumomab Tiuxetan (Zevalin) + Rituximab
Normalized name: ibritumomab tiuxetan
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
Study: NCT03569995
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500 mg/m2 + 5%DW 500 mL IVF Begin with 50 mg/hr (increase by 50 mg/hr per 30 min until 400 mg/hr is reached)
Study: NCT01798264
Drug: ITCA 650 (exenatide in DUROS)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03569995
Drug: Cytarabine Injection
Normalized name: cytarabine Injection
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3000 mg/m2 + 5%DW 200 mL IVF over 2 hrs steroid eye drop 0.1%, 2 drops q 6hrs, on days 1-9
Study: NCT02601378
Drug: LXS196 and HDM201
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LXS196 in combination with HDM201
Study: NCT04220606
Drug: Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)
Normalized name: glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01503658
Drug: Clopidogrel+Aspirin
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg, Aspirin 100 mg
Study: NCT00865384
Drug: Mirtazapine 15 mg tablets, single dose
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions
Study: NCT02102815
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 0.15mg/kg mixed with NSS up to 50 mL IV slowly push over 5 minutes
Study: NCT02183311
Drug: BI 1356 BS - single rising dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183311
Drug: BI 1356 BS - multiple rising dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00636545
Drug: Oblimersen (Genasense)
Normalized name: oblimersen
DrugBank: Oblimersen (DB13811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT04415073
Drug: SNDX-6352
Normalized name: anti-Csf1R monoclonal antibody SNDX-6352
DrugBank: Axatilimab (DB16388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNDX-6352
Study: NCT00521521
Drug: docetaxel and cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00521521
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03546855
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500mg/d po,28 days as one cycle
Study: NCT00697671
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
Study: NCT00697671
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
Study: NCT01904162
Drug: 400 mg finafloxacin (2 x 200 mg tablets)
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01017250
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS